The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 5, 2015, Pages 527-535

  Han, Xu ^a   Zhang, Chunyan ^a   Tang, Min ^a   Xu, Xuefeng ^a   Liu, Lingxiao ^a   Ji, Yuan ^a   Pan, Baishen ^a   Lou, Wenhui ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chromogranin A; Liver metastases; Nomogram; Nonfunctional pancreatic neuroendocrine tumors; Survival; Therapeutic response; Tumor burden

Indexed keywords

CHROMOGRANIN A; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; LIVER SURGERY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; NONFUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; SURVIVAL PREDICTION; SYSTEMIC THERAPY; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; ADOLESCENT; AGED; BLOOD; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SECONDARY; SURVIVAL RATE; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHROMOGRANIN A; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NOMOGRAMS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; YOUNG ADULT;

EID: 84927168251     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000332     Document Type: Article

References (27)

1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19:1727-1733.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063-3072.
3. Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas 2014; 43:526-531.
4. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157-176.
5. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15:e8-e21.
6. Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27:4293-4299.
7. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314:1145-1151.
8. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89:302-307.
9. Peracchi M, Conte D, Gebbia C, Penati C, Pizzinelli S, Arosio M, et al. Plasma chromogranin A in patients with sporadic gastro-enteropancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003; 148:39-43.
10. Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013; 31:1188-1195.
11. Giovanella L, La Rosa S, Ceriani L, Uccella S, Erba P, Garancini S. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 1999; 14:160-166.
12. Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78:1102-1107.
13. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl 2):S69-S72.
14. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427-2443.
15. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an 'on/off' switch controlling dense-core secretory granule biogenesis. Cell 2001; 106:499-509.
16. Korse CM, Taal BG, Vincent A, van Velthuysen ML, Baas P, Buning-Kager JC, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer 2012; 48:662-671.
17. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18 (Suppl 1):S17-S25.
18. Nikou GC, Marinou K, Thomakos P, Papageorgiou D, Sanzanidis V, Nikolaou P, et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 2008; 8:510-519.
19. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8:685-690.
20. Elias D, Lefevre JH, Duvillard P, Goere D, Dromain C, Dumont F, Baudin E. Hepatic metastases from neuroendocrine tumors with a 'thin slice' pathological examination: they are many more than you think. Ann Surg 2010; 251:307-310.
21. Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, et al. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology 2012; 95:344-350.
22. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762-4771.
23. Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol 2010; 105:2072-2078.
24. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28:69-76.
25. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005-2012.
26. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6:820-827.
27. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102:1106-1112.